What steps in the development of an anti-TNF biosimilar such as infliximab ensure the likelihood that the reference product and biosimilar produce similar clinical effects?

What steps in the development of an anti-TNF biosimilar such as infliximab ensure the likelihood that the reference product and biosimilar produce similar clinical effects?

What are the analytical steps in the development process of an anti-TNF biosimilar such as infliximab that will ensure the likelihood that the reference product and biosimilar produce similar clinical effects in patients?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Jonathan Kay, MD

Jonathan Kay, MD

Director of Clinical Research
Rheumatology Division
Professor of Medicine
University of Massachusetts Medical School
Worcester, MA